Strategies for tumor-directed delivery of siRNA

Bibliography

• Dickerson EB, Blackburn WH, Smith MH, Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 2010;10:1-11
   PubMed Web of Science ®Google Scholar
• Kalota A, Shetzline SE, Gewirtz AM. Progress in the development of nucleic acid therapeutics for cancer. Cancer Biol Ther 2004;3:4-12
   PubMed Web of Science ®Google Scholar
• Abdelrahim M, Safe S, Baker C, RNAi and cancer: implications and applications. J RNAi Gene Silencing 2006;2:136-45
   PubMedGoogle Scholar
• Martinez J, Patkaniowska A, Urlaub H, Single-stranded antisense siRNAsguide target RNA cleavage in RNAi. Cell 2002;110:563-74
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11
   PubMed Web of Science ®Google Scholar
• Tuschl T, Zamore PD, Lehmann R, Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 1999;13:3191-7
   PubMed Web of Science ®Google Scholar
• Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999;286:950-2
   PubMed Web of Science ®Google Scholar
• Jackson AL, Linsley PS. Noise amidst the silence: off-targeteffects of siRNAs? Trends Genet 2004;20:521-4
   PubMed Web of Science ®Google Scholar
• Song JJ, Smith SK, Hannon GJ, Crystal structure of Argonaute and its implications for RISC slicer activity. Science 2004;305:1434-7
   PubMed Web of Science ®Google Scholar
• Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007;117:3623-32
   PubMed Web of Science ®Google Scholar
• Doench J, Petersen C, Sharp P. siRNAs can function as miRNAs. Genes Dev 2003;17:438-42
   PubMed Web of Science ®Google Scholar
• Martinez J, Patkaniowska A, Urlaub H, Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002;110:563-74
   PubMed Web of Science ®Google Scholar
• Pai SI, Lin YY, Macaes B, Prospects of RNA interference therapy for cancer. Gene Ther 2006;13:464-77
   PubMed Web of Science ®Google Scholar
• Hossain S, Stanislaus A, Chua MJ, Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J Control Release 2010;147:101-8
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99
   PubMed Web of Science ®Google Scholar
• Futreal PA, Coin L, Marshall M, A census of human cancer genes. Nat Rev Cancer 2004;4:177-83
   PubMed Web of Science ®Google Scholar
• Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001;8:161-73
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65
   PubMed Web of Science ®Google Scholar
• Wohlbold L, van der Kuip H, Miething C, Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003;102:2236-9
   PubMed Web of Science ®Google Scholar
• Chen J, Wall NR, Kocher K, Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest 2004;113:1784-91
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. Gefitinibsensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004;305:1163-7
   PubMed Web of Science ®Google Scholar
• Yang G, Cai KQ, Thompson-Lanza JA, Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004;279:4339-45
   PubMed Web of Science ®Google Scholar
• Choudhury A, Charo J, Parapuram SK, Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004;108:71-7
   PubMed Web of Science ®Google Scholar
• Sithanandam G, Fornwald LW, Fields J, Anderson LM. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 2005;24:1847-59
   PubMed Web of Science ®Google Scholar
• Kaulfuss S, Burfeind P, Gaedcke J, Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther 2009;8:821-33
   PubMed Web of Science ®Google Scholar
• Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 2003;22:6589-97
   PubMed Web of Science ®Google Scholar
• Aharinejad S, Sioud M, Lucas T, Target validation using RNA interference in solid tumors. Methods Mol Biol 2007;361:227-38
   PubMedGoogle Scholar
• Aharinejad S, Paulus P, Sioud M, Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004;64:5378-84
   PubMed Web of Science ®Google Scholar
• Walters DK, Stoffregen EP, Heinrich MC, RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood 2005;105:2952-4
   PubMed Web of Science ®Google Scholar
• Ma PC, Jagadeeswaran R, Jagadeesh S, Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004;23:1448-56
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. J Am Coll Surg 2004;198:53-959
   Google Scholar
• Verma UN, Surabhi RM, Schmaltieg A, Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300
   PubMed Web of Science ®Google Scholar
• van de Wetering M, Oving I, Muncan V, Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003;4:609-15
   PubMed Web of Science ®Google Scholar
• Wang YH, Liu S, Zhang G, Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005;7:R220-8
   PubMed Web of Science ®Google Scholar
• Chen LM, Le HY, Qin RY, Reversal of the phenotype by K-rasval12 silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. World J Gastroenterol 2005;11:831-8
   PubMed Web of Science ®Google Scholar
• Zhu H, Liang ZY, Ren XY, Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo. Cancer Biol Ther 2006;5:1693-8
   PubMed Web of Science ®Google Scholar
• Wang W, Wang CY, Dong JH, Identification of effective siRNA against K-ras in human pancreatic cancer cell line MiaPaCa-2 by siRNA expression cassette. World J Gastroenterol 2005;11:2026-31
   PubMed Web of Science ®Google Scholar
• Jilaveanu LB, Zito CR, Aziz SA, C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res 2009;15:5704-13
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang N, Liang S, RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biol Ther 2004;3:1283-9
   PubMed Web of Science ®Google Scholar
• Zhang X, Deng HX, Zhao X, RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitro and in vivo. Oncology 2009;77:22-32
   PubMed Web of Science ®Google Scholar
• Gagnon V, Mathieu I, Sexton E, AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004;94:785-95
   PubMed Web of Science ®Google Scholar
• Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene 2005;24:5482-91
   PubMed Web of Science ®Google Scholar
• Guo J, Verma UN, Gaynor RB, Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 2004;10:3333-41
   PubMed Web of Science ®Google Scholar
• Dohjima T, Lee NS, Li H, Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther 2003;7:811-16
   PubMed Web of Science ®Google Scholar
• Chansky HA, Barahmand-Pour F, Mei Q, Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res 2004;22:910-17
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. Functions of the retinoblastoma protein. Bioessays 1999;21:950-8
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50
   PubMed Web of Science ®Google Scholar
• Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-8
   PubMed Web of Science ®Google Scholar
• DuPree EL, Mazumder S, Almasan A. Genotoxic stress induces expression of E2F4, leading to its association with p130 in prostate carcinoma cells. Cancer Res 2004;64:4390-3
   PubMed Web of Science ®Google Scholar
• Pai SI, Lin YY, Macaes B, Prospects of RNA interference therapy for cancer. Gene Ther 2006;13:464-77
   PubMed Web of Science ®Google Scholar
• Danovi D, Meulmeester E, Pasini D, Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004;24:5835-43
   PubMed Web of Science ®Google Scholar
• Purow BW, Haque RM, Noel MW, Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005;65:2353-63
   PubMed Web of Science ®Google Scholar
• Butz K, Ristriani T, Hengstermann A, siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003;22:5938-45
   PubMed Web of Science ®Google Scholar
• Yuan J, Yan R, Kramer A, Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004;23:5843-52
   PubMed Web of Science ®Google Scholar
• Radulovich N, Pham NA, Strumpf D, Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma. Mol Cancer 2010;9:1-15
   PubMedGoogle Scholar
• Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell 2009;36:469-76
   PubMed Web of Science ®Google Scholar
• Gumina MR, Xu C, Chiles TC. Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. Cell Cycle 2010;9:820-8
   PubMed Web of Science ®Google Scholar
• Xiao Z, Xue J, Sowin TJ, A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005;24:1403-11
   PubMedGoogle Scholar
• El-Gazzar A, Wittinger M, Perco P, The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential. Gynecol Oncol 2010;117:451-9
   PubMed Web of Science ®Google Scholar
• Abedini MR, Qiu Q, Yan X, Possible role of FLICElike inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 2004;23:6997-7004
   PubMed Web of Science ®Google Scholar
• Ruckert F, Samm N, Lehner AK, Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. BMC Cancer 2010;10:379
   PubMedGoogle Scholar
• Lima RT, Martins LM, Guimaraes JE, Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004;11:309-16
   PubMed Web of Science ®Google Scholar
• Zhu H, Guo W, Zhang L, Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005;4:451-6
   PubMed Web of Science ®Google Scholar
• Taniai M, Grambihler A, Higuchi H, Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004;64:3517-24
   PubMed Web of Science ®Google Scholar
• Ning S, Fuessel S, Kotzsch M, siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 2004;25:1065-71
   PubMed Web of Science ®Google Scholar
• Kappler M, Bache M, Bartel F, Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 2004;11:186-93
   PubMed Web of Science ®Google Scholar
• Uchida H, Tanaka T, Sasaki K, Adenovirus-mediated transfer of siRNA against surviving induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004;10:162-71
   PubMed Web of Science ®Google Scholar
• Cheng SQ, Wang WL, Yan W, Knockdown of survivin gene expression by RNAi induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721. World J Gastroenterol 2005;11:756-9
   PubMed Web of Science ®Google Scholar
• Hatano M, Mizuno M, Yoshida J. Enhancement of C2-ceramide antitumor activity by small interfering RNA on X chromosome-linked inhibitor of apoptosis protein in resistant human glioma cells. J Neurosurg 2004;101:119-27
   PubMed Web of Science ®Google Scholar
• July LV, Beraldi E, So A, Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004;3:223-32
   PubMed Web of Science ®Google Scholar
• He J, Chang LJ. Functional characterization of hepatomaspecific stem cell antigen-2. Mol Carcinog 2004;40:90-103
   PubMed Web of Science ®Google Scholar
• Liao X, Zhang L, Thrasher JB, Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factorrelated apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003;2:1215-22
   PubMed Web of Science ®Google Scholar
• Izeradjene K, Douglas L, Delaney A, Houghton JA. Influence of casein kinase II in tumor necrosis factor-related apoptosis- inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 2004;10:6650-60
   PubMed Web of Science ®Google Scholar
• Gandellini P, Folini M, Bandiera R, Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol 2007;73:1703-14
   PubMed Web of Science ®Google Scholar
• Nakamura M, Masutomi K, Kyo S, Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 2005;16:859-68
   PubMed Web of Science ®Google Scholar
• Natarajan S, Chen Z, Wancewicz EV, Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity. Oligonucleotides 2004;14:263-73
   PubMed Web of Science ®Google Scholar
• Mo Y, Gan Y, Song S, Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003;63:579-85
   PubMed Web of Science ®Google Scholar
• de Souza Nascimento P, Alves G, Fiedler W. Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells. Oncol Rep 2006;16:423-8
   PubMed Web of Science ®Google Scholar
• Zhang PH, Zou L, Tu ZG. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 2006;131:143-9
   PubMed Web of Science ®Google Scholar
• Dong X, Liu A, Zer C, siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer 2009;9:1-10
   PubMedGoogle Scholar
• Patry C, Bouchard L, Labrecque P, Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res 2003;63:7679-88
   PubMed Web of Science ®Google Scholar
• Takei Y, Kadomatsu K, Yuzawa Y, A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004;64:3365-70
   PubMed Web of Science ®Google Scholar
• Chen Y, Jiang L, She F, Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Mol Cell Biochem 2010;345:77-89
   PubMed Web of Science ®Google Scholar
• Yin Y, Cao LY, Wu WQ, Blocking effects of siRNA on VEGF expression in human colorectal cancer cells. World J Gastroenterol 2010;16:1086-92
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Ansari A, Xu J, Cancer siRNA therapy by tumor selective delivery with ligandtargeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:1-10
   PubMed Web of Science ®Google Scholar
• Lui Z, Ma Q, Wang X, Inhibiting tumor growth of colorectal cancer by blocking the expression of vascular endothelial growth factor receptor 3 using interference vector-based RNA interference. Int J Mol Med 2010;25:59-64
   PubMed Web of Science ®Google Scholar
• Salvi A, Arici B, De Petro G, Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 2004;3:671-8
   PubMed Web of Science ®Google Scholar
• Huang HY, Jiang ZF, Li QX, Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator. Cancer Invest 2010;28:689-97
   PubMed Web of Science ®Google Scholar
• Gondi CS, Rao JS. Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol 2009;487:267-81
   PubMedGoogle Scholar
• Gondi CS, Lakka SS, Dinh DH, RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004;23:8486-96
   PubMed Web of Science ®Google Scholar
• Nalla AK, Gorantla B, Gondi CS, Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther 2010;17:599-613
   PubMed Web of Science ®Google Scholar
• Lakka SS, Gondi CS, Dinh DH, Specific interference of uPAR and MMP-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth and angiogenesis in gliomas. J Biol Chem 2005;280:21882-92
   PubMed Web of Science ®Google Scholar
• Liu N, Bi F, Pan Y, Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res 2004;10:6239-47
   PubMed Web of Science ®Google Scholar
• Wu M, Wu ZF, Rosenthal DT, Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer 2010;116:2768-82
   PubMed Web of Science ®Google Scholar
• Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 2003;63:4801-4
   PubMed Web of Science ®Google Scholar
• Li H, Yang W, Chen PW, Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases. Invest Ophthalmol Vis Sci 2009;50:5522-8
   PubMed Web of Science ®Google Scholar
• Lee EJ, Mircean C, Shmulevich I, Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005;4:1-8
   PubMedGoogle Scholar
• Lipscomb EA, Dugan AS, Rabinovitz I, Use of RNA interference to inhibit integrin (alpha6beta4)-mediated invasion and migration of breast carcinoma cells. Clin Exp Metastasis 2003;20:569-76
   PubMed Web of Science ®Google Scholar
• Osta WA, Chen Y, Mikhitarian K, EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-24
   PubMed Web of Science ®Google Scholar
• Abbasi M, Lavasanifar A, Berthiaume LG, Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells. Cancer 2010;116:5544-54
   Google Scholar
• Susa M, Iyer AK, Ryu K, Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5:e10764
   PubMed Web of Science ®Google Scholar
• Patutina OA, Mironova NL, Popova NA, The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer 2010;10:1-11
   PubMedGoogle Scholar
• Xiong XB, Uludag H, Lavasanifar A. Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials 2010;31:5886-93
   PubMed Web of Science ®Google Scholar
• Chen Y, Bathula SR, Li J, Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010;285:22639-50
   PubMed Web of Science ®Google Scholar
• Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3(7):833-8
   PubMed Web of Science ®Google Scholar
• Huang Y, Anderle P, Bussey KJ, Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-301
   PubMed Web of Science ®Google Scholar
• Ryther RC, Flynt AS, Phillips JA III, siRNA therapeutics: big potential from small RNAs. Gene Ther 2005;12:5-11
   PubMed Web of Science ®Google Scholar
• van de Water FM, Boerman OC, Wouterse AC, Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006;34:1393-7
   PubMed Web of Science ®Google Scholar
• Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003;9:1034-48
   PubMed Web of Science ®Google Scholar
• Harborth J, Elbashir SM, Vandenburgh K, Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 2003;13:83-105
   PubMedGoogle Scholar
• Czauderna F, Fechtner M, Dames S, Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31:2705-16
   PubMed Web of Science ®Google Scholar
• Braasch DA, Jensen S, Liu Y, RNA interference in mammalian cells by chemically modified RNA. Biochemistry 2003;42:7967-75
   PubMed Web of Science ®Google Scholar
• Layzer JM, McCaffrey AP, Tanner AK, In vivo activity of nuclease-resistant siRNAs. RNA 2004;10:766-71
   PubMed Web of Science ®Google Scholar
• Hall AH, Wan J, Shaughnessy EE, RNA interference using boranophosphate siRNAs: structure–activity relationships. Nucleic Acids Res 2004;32:5991-6000
   PubMed Web of Science ®Google Scholar
• Dallas A, Vlassov AV. RNAi: a novel antisense technology and its therapeutic potential. Med Sci Monit 2006;12:RA67-74
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Lockridge JA, Shaw L, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-7
   PubMed Web of Science ®Google Scholar
• Judge AD, Robbins M, Tavakoli I, Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009;119:661-73
   PubMed Web of Science ®Google Scholar
• Wu SY, Putral LN, Liang M, Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharm Res 2009;26:512-22
   PubMed Web of Science ®Google Scholar
• Wu SY, Singhania A, Burgess M, Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. Gene Ther 2010;18:14-22
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu JJ, Huang L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 2010;18:828-34
   PubMed Web of Science ®Google Scholar
• Li SD, Chen YC, Hackett MJ, Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2008;16:163-9
   PubMed Web of Science ®Google Scholar
• Landen CN Jr, Chavez-Reyes A, Bucana C, Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-18
   PubMed Web of Science ®Google Scholar
• Halder J, Kamat AA, Landen CN Jr, Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24
   PubMed Web of Science ®Google Scholar
• Shahzad MM, Lu C, Lee JW, Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009;8:1027-34
   PubMed Web of Science ®Google Scholar
• Merritt WM, Lin YG, Spannuth WA, Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. Natl Cancer Inst 2008;100:359-72
   Google Scholar
• Yano J, Hirabayashi K, Nakagawa S, Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004;10:7721-6
   PubMed Web of Science ®Google Scholar
• Futami K, Kumagai E, Makino H, Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models. Cancer Sci 2008;99:1227-36
   Google Scholar
• Pal A, Ahmad A, Khan S, Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 2005;26:1087-91
   PubMed Web of Science ®Google Scholar
• Bisanz K, Yu J, Edlund M, Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005;12:634-43
   PubMed Web of Science ®Google Scholar
• Santel A, Aleku M, Keil O, RNA interference in the mouse vascular endothelium by systemic administration of siRNA–lipoplexes for cancer therapy. Gene Ther 2006;13:1360-70
   PubMed Web of Science ®Google Scholar
• Yoshizawa T, Hattori Y, Hakoshima M, Folate-linked lipidbased nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm 2008;70:718-25
   PubMed Web of Science ®Google Scholar
• Hogrefe RI, Lebedev AV, Zon G, Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 2006;25:889-907
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Zon G, Rait A, Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006;17:117-24
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Rait A, Zhou Q, Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007;67:2938-43
   PubMed Web of Science ®Google Scholar
• Daniels TR, Delgado T, Rodriguez JA, The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006;121:144-58
   PubMed Web of Science ®Google Scholar
• Lee YK, Kim KS, Kim JS, Leukemia-Specific siRNA Delivery by Immunonanoplexes Consisting of Anti-JL1 Minibody Conjugated to Oligo-9 Arg-Peptides. Mol Cells 2010;29:457-62
   PubMed Web of Science ®Google Scholar
• Kim TJ, Park SH. Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia. J Korean Med Sci 1998;13:455-8
   PubMedGoogle Scholar
• Park WS, Bae YM, Chung DH, A cell surface molecule, JL1; a specific target for diagnosis andtreatment of leukemias. Leukemia 1998;12:1583-90
   PubMed Web of Science ®Google Scholar
• Shin YK, Choi YL, Choi EY, Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications. Cancer Immunol Immunother 2003;52:506-12
   PubMed Web of Science ®Google Scholar
• Goffinet C, Keppler OT. Efficient nonviral gene delivery into primary lymphocytes from rats and mice. FASEB J 2006;20:500-2
   PubMed Web of Science ®Google Scholar
• Xia CF, Zhang Y, Zhang Y, Intravenous siRNA of brain cancer with receptor targeting and avidin–biotin technology. Pharm Res 2007;24:2309-16
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Ansari A, Xu J, Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:1-10
   PubMed Web of Science ®Google Scholar
• Hobel S, Koburger I, John M, Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010;12:287-300
   PubMed Web of Science ®Google Scholar
• Xu CX, Jere D, Jin H, Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med 2008;178:60-73
   PubMed Web of Science ®Google Scholar
• Grzelinski M, Urban-Klein B, Martens T, RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006;17:751-66
   PubMed Web of Science ®Google Scholar
• Alshamsan A, Hamdy S, Samuel J, The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 2010;31:1420-8
   PubMed Web of Science ®Google Scholar
• Song E, Zhu P, Lee SK, Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-17
   PubMed Web of Science ®Google Scholar
• Choi YS, Lee JY, Suh JS, The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010;31:1429-43
   PubMed Web of Science ®Google Scholar
• Heidel JD, Yu Z, Liu JY, Administration in nonhuman primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 2007;104:5715-21
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Heidel JD, Bartlett DW, Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Su H, Hildebrant IJ, Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007;104:15549-15
   PubMed Web of Science ®Google Scholar
• Takei Y, Kadomatsu K, Yuzawa Y, A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004;64:3365-70
   PubMed Web of Science ®Google Scholar
• Takeshita F, Minakuchi Y, Nagahara S, Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005;102:12177-82
   PubMed Web of Science ®Google Scholar
• Takeshita F, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci 2006;97:689-96
   PubMed Web of Science ®Google Scholar
• Minakuchi Y, Takeshita F, Kosaka N, Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004;32:1-7
   PubMed Web of Science ®Google Scholar
• Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009;61:850-62
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92
   PubMed Web of Science ®Google Scholar
• Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010;277:4814-27
   PubMed Web of Science ®Google Scholar
• Katze MG, Wambach M, Wong ML, Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNA-activated, 68,000-Mr protein kinase in a cell-free system. Mol Cell Biol 1991;11:5497-505
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-8
   PubMed Web of Science ®Google Scholar